Buy Cjc No Dac Ipa Research Compound
When investigative teams seek to buy CJC No DAC Ipa research compound formulations, evaluating analytical rigor and structural integrity is paramount. This specialized dual-peptide combination pairs a truncated growth hormone-releasing hormone (GHRH) analog with a selective ghrelin receptor agonist to facilitate advanced in vitro and preclinical research into pituitary somatotroph signaling.
Quick answer
When investigative teams seek to buy CJC No DAC Ipa research compound formulations, evaluating analytical rigor and structural integrity is paramount. This specialized dual-peptide combination pairs a truncated growth hormone-releasing hormone (GHRH) analog with a selective ghrelin receptor agonist to facilitate advanced in vitro and preclinical research into pituitary somatotroph signaling.
Key takeaways
- Researchers looking to buy CJC No DAC Ipa research compound materials are acquiring a co-formulated, lyophilized peptide complex consisting of [CJC-1295](/research-peptides/cjc-1295-no-dac) No DAC (Modified GRF 1-29) and [Ipamorelin](/research-peptides/ipamorelin).
- To properly utilize this dual formulation in a experimental setting, investigators must analyze the distinct structural biology of both constituent peptides.
- In vitro somatotroph culture studies show that simultaneous activation of the GHRH receptor and GHS-R1a yields a synergistic, rather than merely additive, release of growth hormone.
- Laboratory outcomes depend heavily on chemical purity.
Direct Answer: What Is the CJC No DAC + Ipamorelin Research Compound?
Researchers looking to buy CJC No DAC Ipa research compound materials are acquiring a co-formulated, lyophilized peptide complex consisting of CJC-1295 No DAC (Modified GRF 1-29) and Ipamorelin. This dual-agonist system is specifically designed for laboratory investigation of growth hormone secretagogue receptor synergism, somatotroph signaling cascades, and pulsatile growth hormone dynamics in preclinical research models.
By delivering two distinct molecular pathways—GHRH receptor agonism via Modified GRF 1-29 and selective growth hormone secretagogue receptor (GHS-R1a) activation via Ipamorelin—this combination offers laboratory scientists a validated platform to study complementary endocrine axes without the confounding long-half-life extended kinetics observed in Drug Affinity Complex (DAC) variants.
Molecular Architecture and Receptor Binding Profiles
To properly utilize this dual formulation in a experimental setting, investigators must analyze the distinct structural biology of both constituent peptides. CJC-1295 No DAC, chemically designated as Modified GRF 1-29, is a 29-amino acid tetrasubstituted peptide derivative of natural GHRH(1-29). The amino acid substitutions at positions 2, 8, 15, and 27 (D-Ala2, Gln8, Ala15, and Leu27) confer resistance against enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV), thereby extending its biological half-life in culture media compared to native GHRH.
Ipamorelin, conversely, is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that functions as a highly selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R1a). Unlike earlier generation secretagogues such as GHRP-6 or GHRP-2, preclinical binding assays demonstrate that Ipamorelin exhibits minimal binding affinity for glucocorticoid, mineralocorticoid, or prolactin receptors. When researchers evaluate all research peptides for neuroendocrine pathways, the structural precision of this pairing remains a benchmark for selective receptor engagement.
Preclinical Synergism and GH Secretion Kinetics
In vitro somatotroph culture studies show that simultaneous activation of the GHRH receptor and GHS-R1a yields a synergistic, rather than merely additive, release of growth hormone. GHRH receptor activation initiates a Gs protein-coupled cascade, stimulating intracellular adenylate cyclase and raising cyclic adenosine monophosphate (cAMP) levels. Concurrently, Ipamorelin binding to GHS-R1a triggers a Gq protein-coupled pathway that activates phospholipase C (PLC), inducing inositol trisphosphate (IP3)-mediated calcium mobilization from intracellular stores.
Preclinical rodent bioassays confirm that co-administration of Modified GRF 1-29 and Ipamorelin amplifies physiological GH pulse amplitude while preserving natural feedback mechanisms. Because CJC-1295 No DAC lacks the lysine-maleimide complex responsible for irreversible serum albumin binding, the combination produces acute, controlled secretory spikes ideal for investigating physiological secretion profiles in preclinical research models.
Evaluating Chemical Purity: RP-HPLC and Mass Spectrometry
Laboratory outcomes depend heavily on chemical purity. Minor sequence truncation, deamidation, or incomplete deprotection during solid-phase peptide synthesis (SPPS) can generate antagonist artifacts that obscure receptor binding assays. Therefore, when laboratories decide to buy CJC No DAC Ipa research compound inventory, verifying purity through rigorous analytical methodologies is essential.
PX1 Research subjects every synthesis lot to high-performance liquid chromatography (RP-HPLC) coupled with electrospray ionization mass spectrometry (ESI-MS). RP-HPLC isolates individual peptide peaks based on hydrophobic interactions, establishing baseline purity metrics exceeding 99.0%. ESI-MS verifies the exact molecular mass of both CJC-1295 No DAC (3,367.9 Da) and Ipamorelin (711.9 Da), confirming sequence fidelity and the total absence of residual counterions or organic synthesis reagents.
Biological Safety Protocols: Endotoxin Limits and Sterility Verification
For cell culture assays, primary tissue cultures, and animal models, bacterial endotoxins (lipopolysaccharides) represent a severe confounding variable. Excess endotoxins trigger inflammatory cytokine cascades (such as IL-6 and TNF-alpha) that interfere with somatotroph signaling and skew metabolic end-points.
PX1 Research mandates strict biological safety protocols for every lot. Our compounds undergo quantitative Chromogenic Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels remain strictly below <0.01 EU/mg. Furthermore, processing in ISO 6 / GMP-compliant cleanrooms ensures that the final lyophilized matrix is sterile and free from microbial contamination, yielding consistent, reproducible experimental data.
Laboratory Reconstitution Protocols and Solvent Compatibility
Proper reconstitution technique is vital to preserve peptide secondary structure and avoid aggregation. Lyophilized peptide cakes should be reconstituted using laboratory-grade bacteriostatic water (0.9% benzyl alcohol) or sterile endotoxin-free water, depending on the specific sensitivity of the cellular model under evaluation.
Investigators should introduce the solvent along the internal glass wall of the vial under gentle vacuum release, allowing the liquid to trickle over the cake. High-shear vortexing or mechanical agitation must be strictly avoided, as physical shearing can disrupt peptide hydrogen bonding and precipitate insoluble aggregates. Gentle swirl rotation ensures complete dissolution into a clear, colorless solution suitable for high-precision micro-pipetting.
Stability, Thermal Degradation, and Storage Requirements
Lyophilized CJC No DAC + Ipamorelin complexes remain stable at -20°C to -80°C for up to 24 months when protected from light and moisture. The desiccated matrix maintains structural integrity through repeated ambient transit cycles, provided thermal stress is minimized.
Once reconstituted into an aqueous phase, degradation rates increase via hydrolysis and methionine oxidation. Reconstituted aliquots must be stored at 2°C to 8°C and evaluated within 21–28 days. For extended research timelines, researchers should divide reconstituted stock solutions into single-use micro-aliquots and store them at -80°C to prevent freeze-thaw degradation cycles.
Comparative Analysis of Growth Hormone Secretagogues
In secretagogue research, scientists frequently evaluate multiple structural classes to select the appropriate compound for their specific protocol. The table below highlights the comparative analytical parameters of key secretagogues studied in preclinical literature:
When contrasted with CJC-1295 DAC, which features a maleimido-propionic acid linker for extended albumin binding, the No DAC variant provides transient receptor activation. Meanwhile, compared to non-selective agents like GHRP-2 research peptide, isolated Ipamorelin research compound or its co-formulation maintains superior receptor selectivity. Furthermore, while Tesamorelin serves as a specialized GHRH analog for lipodystrophy research, the CJC No DAC + Ipamorelin blend remains the primary choice for studying dual GHRH-R/GHS-R1a receptor cross-talk.
Sourcing Standards and USA Manufacturing Protocols at PX1 Research
Procuring high-grade reagents requires complete supply chain transparency. PX1 Research manufactures all research compounds within state-of-the-art USA facilities operating under ISO 9001:2015 and ISO 17025 accredited quality management standards.
Every batch is assigned a unique lot number linked to its raw material lineage, synthesis logs, and independent third-party Certificates of Analysis (COAs). Orders placed Monday through Friday ship same-day from our primary logistics hubs in California and Arizona, ensuring minimal transit times and heat exposure. Institutional accounts requiring bulk supply configurations can coordinate through our bulk research account division for custom synthesis and dedicated batch reservation.
Frequently Asked Questions
What is the primary rationale to buy cjc no dac ipa research compound for laboratory models?
Investigators buy CJC No DAC Ipa research compound formulations to analyze the synergistic signaling between GHRH receptor agonists (CJC-1295 No DAC) and GHS-R1a agonists (Ipamorelin) without the prolonged half-life associated with albumin-bound DAC variants.
How does CJC-1295 No DAC differ from CJC-1295 with DAC in preclinical studies?
CJC-1295 No DAC (Modified GRF 1-29) lacks the Drug Affinity Complex (maleimide linker). Consequently, it exhibits a shorter half-life (approximately 30 minutes in plasma) ideal for pulsatile GH research, whereas CJC-1295 DAC binds albumin to extend its half-life to several days.
What is the mechanism of action behind the CJC No DAC and Ipamorelin combination?
The combination acts via dual pathway activation: CJC-1295 No DAC stimulates GHRH receptors to increase intracellular cAMP, while Ipamorelin activates GHS-R1a to trigger IP3-mediated intracellular calcium release, resulting in synergistic growth hormone pulse amplification.
How should researchers verify purity when deciding to buy cjc no dac ipa research compound?
Researchers should demand lot-specific third-party Certificates of Analysis (COAs) featuring Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity (≥99%) and Electrospray Ionization Mass Spectrometry (ESI-MS) for exact molecular weight identity.
What solvent is recommended for reconstituting the CJC No DAC Ipa research blend?
Bacteriostatic water containing 0.9% benzyl alcohol is recommended for multi-use laboratory sampling over a 30-day period. For specialized cell culture assays sensitive to preservatives, sterile endotoxin-free water should be utilized.
What are the storage conditions for lyophilized vs. reconstituted CJC No DAC Ipa?
Lyophilized vials should be stored at -20°C to -80°C for long-term stability up to 24 months. Reconstituted aqueous solutions should be refrigerated at 2°C to 8°C and used within 21–28 days, or micro-aliquoted and stored at -80°C.
Why is endotoxin testing critical when procuring research peptides?
Bacterial endotoxins introduce severe artifacts in preclinical assays by provoking inflammatory signaling pathways. PX1 Research guarantees endotoxin levels below <0.01 EU/mg using quantitative LAL testing.
Does Ipamorelin trigger significant cortisol or prolactin release in vitro?
No. Preclinical binding profiles demonstrate that Ipamorelin is highly selective for GHS-R1a, producing negligible stimulation of ACTH, cortisol, or prolactin secretion compared to older secretagogues such as GHRP-2 or GHRP-6.
What analytical techniques confirm the molecular identity of both peptides in a blend?
ESI-MS isolates mass-to-charge ratios to confirm the presence of both molecular species (CJC-1295 No DAC at 3,367.9 Da and Ipamorelin at 711.9 Da), while dual-peak HPLC integration establishes quantitative stoichiometry.
How does PX1 Research ship CJC No DAC Ipa research compounds to maintain integrity?
All orders ship same-day (Monday through Friday) from climate-controlled facilities in California and Arizona using protective packaging designed to minimize temperature flux and physical vibration during transit.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.